<DOC>
	<DOCNO>NCT00794677</DOCNO>
	<brief_summary>The purpose study test effect Zetia™ ( ezetimibe ) 10 milligram ( mg ) absorption oxysterol blood follow meal contain oxysterol .</brief_summary>
	<brief_title>Effects Ezetimibe Absorption Oxidized Cholesterol</brief_title>
	<detailed_description>There number cholesterol-lowering drug available low blood cholesterol healthy level . Zetia™ ( ezetimibe ) 10 mg available prescription treatment high cholesterol . While Zetia show inhibit absorption dietary cholesterol bloodstream , effect oxysterol absorption diet completely evaluate .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>Not currently pregnant lactate highly unlikely conceive Body Mass Index ( BMI ) 2030 kilogram per meter square ( kg/m2 ) inclusive . Body weight , report patient , stable ( ±2 kg ) &gt; 6 week Plasma low density lipoprotein cholesterol ( LDLC ) 130 180 milligram per deciliter ( mg/dL ) inclusive . Note : One retest allow . Triglyceride ( TG ) concentration ≤150 mg/dL . Note : One retest allow . Fasting blood glucose &lt; 110 mg/dL hemoglobin A1c ( HbA1C ) ≤ 6 percent Visit 1 . Note : One retest allow . Liver transaminases ( ALT , AST ) ≤1.5 x upper limit normal ( ULN ) active liver disease . Note : One retest allow . Creatine Phosphokinase ( CPK ) ≤2x ULN . Note : One retest allow . Willingness maintain stable diet duration study . Can understand comply study procedure sign write informed consent . Patient ≥80 precent compliant dose Placebo RunIn Period , opinion investigator , able maintain ≥80 percent therapy compliance active treatment period study . Lipidlowering therapy replacement therapy study medication consider inappropriate investigator . Consumes average 2 alcoholic drink per day . Smokes . Currently engage vigorous exercise regimen intensive exercise bout &gt; 4x per month . Treated investigational drug within 30 day Visit 1 . Hypersensitivity intolerance ezetimibe component medication . Any condition situation pose risk patient interfere participation study . Congestive heart failure . Uncontrolled cardiac arrhythmia . History myocardial infarction , stroke , clinical manifestation coronary , cerebral , peripheral vascular disease . Uncontrolled hypertension Impaired renal function , nephrotic syndrome clinically significant renal disease Visit 1 . Active chronic hepatobiliary hepatic disease . History irritable bowel syndrome , ileal bypass , gastric bypass gastrointestinal disorder/condition associate malabsorption . Uncontrolled endocrine metabolic disease know influence serum lipid lipoprotein . Type I Type II diabetes mellitus . Disorders hematologic , digestive , central nervous system include cerebrovascular disease degenerative disease would limit study evaluation participation . Human Immunodeficiency Virus ( HIV ) positive . History cancer within past 5 year ( except successfully treat basal squamous cell carcinoma ) . History uncontrolled psychiatric illness drug/alcohol abuse within past 5 year . Individuals psychiatric illness adequately control stable pharmacotherapy may enrol discretion investigator . Lipidlowering agent take within 6 week fibrates take within 8 week prior visit 3 . Cardiovascular medication acceptable provided patient stable regimen least 6 week prior Visit 3 indicate willingness continue stable regimen duration study . Supplementation antioxidant beyond standard multivitamin duration study . Psyllium , fiberbased laxative , and/or counter ( OTC ) therapies know affect serum lipid level take within 6 week Visit 3 . Female patient receive hormone replacement therapy , estrogen antagonist/agonist hormonal contraceptive . Treatment cyclosporine except ophthalmic indication Antiobesity medication orlistat sibutramine take within 3 month prior Visit 1 . Therapeutic dos systemic corticosteroid except inhaled steroid therapy ( example , Pulmicort® ) maintain stable dose regimen least 6 week prior randomization ( Visit 3 ) throughout duration study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Hypercholesterolemia</keyword>
	<keyword>Oxysterol</keyword>
	<keyword>Ezetimibe</keyword>
	<keyword>Zetia</keyword>
</DOC>